CRYSTAL LAKE, Ill.—Aptar Pharma and Kali Care have entered into a partnership to address the challenge of monitoring adherence in ophthalmic clinical trials. The partnership is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials, according to a statement.
Kali Care, based in Silicon Valley, provides sensor technology which allows clinicians to replace adherence assumptions in clinical trials with collected real-time data.
Using eye drops as a drug delivery system has its own set of challenges that must be recognized and addressed at the clinical level. The firms said clinical trials benefit from more accurate and timely data collection and management. For ophthalmologists, the ability to see the medication adherence score of patients with glaucoma is a powerful tool in managing treatment plans.
Kali Care's monitoring technology integrates smart sensors, data analytics and cloud services. It can result in shorter and more efficient clinical trials. The Kali Care Adherence Score provides critical information for explaining the incongruity between recommended treatment and actual treatment outcomes, the firm said.
Sina Fateh, founder and CEO of Kali Care, said because Aptar Pharma is well-respected for its proven regulatory expertise, it will help his company move forward through approval and compliance processes.
"Clinicians are now able to rely on objective and accurate data. Aptar Pharma's leading dispensing technologies combined with Kali Care's smart sensors, data analytics and cloud services will help make clinical trials more efficient and effective," Fateh and Salim Haffar, president of Aptar Pharma, said in a joint statement. "This allows ophthalmologists to improve risk strategies to distinguish patients requiring minimal support from those who require closer monitoring,"